echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Drug generation note: the Central Commission for Discipline Inspection issued a text, once again named medicine rebates!

    Drug generation note: the Central Commission for Discipline Inspection issued a text, once again named medicine rebates!

    • Last Update: 2021-01-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Pharmaceutical Network January 20, the Central Commission for Discipline Inspection reissigned, named pharmaceutical rebates recently, the Central Commission for Discipline Inspection, the State Supervision Commission website published "new regulations restricting the behavior of pharmaceutical representatives cut off the drug rebate interest chain" article, referring directly to pharmaceutical companies through medical representatives to doctors to send rebates to promote medical corruption.
    above, the deputy secretary of the Party Committee of the Sixth People's Hospital of Shanghai and the secretary of the discipline committee said in an interview that although the problem of kickbacks is harmful, the blame should not be entirely on the medical representatives.
    some pharmaceutical companies in the operating concept of deviation is the deeper reason.
    statistics, between 2016 and 2019, more than half of the country's 100 compulsory drug enterprises were found to have directly or indirectly given kickbacks, of which the most frequent enterprises involved in more than 20 cases in three years, a single case rebate amount of more than 20 million yuan.
    In June this year, nine ministries, including the National Health and Health Commission, the Ministry of Industry and Information Technology, the Ministry of Public Security, the Ministry of Finance, the Ministry of Commerce, the State Administration of Taxation, the State Administration of Market Supervision and Administration, the State Administration of Health Insurance and the State Administration of Traditional Chinese Medicine, jointly issued the Notice on correcting the wrong trend in the field of pharmaceutical purchase and sale and medical services in 2020, pushing the fight against corruption in health care to a higher level.
    the country's medical anti-corruption efforts continue to strengthen, from large to triple-A hospitals, small to township hospitals, community health service centers, are strictly under investigation.
    recently, the Yunnan Provincial Commission for Discipline Inspection issued a message that the legal representatives of four medical enterprises have been detained because of serious disciplinary violations involving Ma Linkun, former vice president of the Yunnan Provincial Hospital for Cardiovascular Disease.
    same time, Guangxi discipline inspection and supervision network released a message, Zhongshan County Chinese medicine hospital director Chen Jianhong suspected of serious disciplinary violations, is currently under the Zhongshan County Commission for Discipline Inspection disciplinary review and supervision investigation.
    addition, Guangxi Discipline Inspection and Supervision Network recently issued a hechi City First People's Hospital, the former deputy party secretary, president Tan Renlin was expelled from the party membership and public office announcement.
    reported that this case is based on Tan Renlin on behalf of the unit to receive kickbacks, a huge amount, suspected of unit bribery.
    On the issue of medical corruption, the Central Commission for Discipline Inspection and Supervision in the National Health And Safety Commission discipline inspection and supervision team responsible for publicly said that will increase pressure transmission, in accordance with the "who is in charge, who is responsible" and "the management industry must manage the wind" requirements, around the outstanding problems in the field of health care, in-depth special rectification.
    combination of drugs, medical anti-corruption escalation according to incomplete statistics, in the past 10 years, involving thousands of cases involving pharmaceutical bribery, often involving pharmaceutical companies, pharmaceutical representatives, doctors.
    and for the treatment of medical bribery, the state has also targeted the introduction of policies to form a strong combination of fists.
    to regulate the behavior of doctors, the relevant departments have been introduced and improved supporting policies and systems.
    as early as 2013, the former National Health and Family Planning Commission, the State Administration of Traditional Chinese Medicine on the formulation of "strengthening the construction of medical and health practices" nine not allowed."
    at the 2020 National Conference on Medical Management, the key points of the work of the Hospital Administration in 2020 were clearly proposed to revise the industry's "nine no" provisions, formulate treatment methods and other supporting systems, and introduce norms of conduct for foreign exchanges between health and health industry personnel.
    To regulate the behavior of pharmaceutical enterprises, with the State Health Insurance Administration issued the pharmaceutical prices and credit evaluation system landing, from 2021 onwards, all involved enterprises involved in the purchase and sale of medicines to give kickbacks or other improper benefits, the enterprises involved will be included in the "black list" of medical enterprises.
    once listed as a "severe" and "particularly serious" equipment enterprise, after which the enterprise products will be disqualified from the network, bidding and distribution.
    , according to the requirements of the pharmaceutical companies are also responsible for the behavior of sales staff or agents, in the event of a loss of trust will be directly traced to the relevant enterprises.
    , the Supreme People's Court and the State Health Insurance Administration signed a Memorandum of Cooperation on the Exchange and Sharing of Information on Commercial Bribery Cases in the Pharmaceutical Sector in September 2020.
    with the 2021 must be implemented in the pharmaceutical recruitment credit evaluation system landed, in the procurement of drugs, medical equipment, medical supplies in the sub-rules have officially entered a full exposure, comprehensive rectification stage.
    , once involved in commercial bribery and other illegal acts of disrepair, the strictest will be directly prohibited from online procurement.
    For regulating the behavior of pharmaceutical representatives, the Measures for the Administration of the Filing of Pharmaceutical Representatives (Trial) formulated by the State Drug Administration have been formally implemented, explicitly requiring pharmaceutical representatives not to undertake the task of drug sales, to carry out sales acts such as collection and handling of purchase and sale bills, and that drug market license holders shall not encourage or imply that pharmaceutical representatives engage in illegal and illegal acts.
    It is understood that after the formal launch of the pharmaceutical representative filing system, drug market license holders need to enter, change, confirm and delete their pharmaceutical representative information on the filing platform designated by the State Drug Administration as required, and medical institutions can check and check the pharmaceutical representative's filing information on the filing platform, so that medical institutions can more quickly and accurately identify the identity of regular pharmaceutical representatives and ensure compliance with the purchase and sale of medicine.
    when a drug market license holder or a pharmaceutical representative gives property or other improper benefits to the persons concerned who use his medicine, he or she will face severe investigation and punishment by the Drug Administration Law and other relevant laws and regulations.
    as written in the above-mentioned Article of the Central Commission for Discipline Inspection, for pharmaceutical representatives, the future can only have excellent academic ability to achieve the original source of the profession.
    whether we have professional drug knowledge, whether we can conduct academic exchanges with doctors under the premise of more standardization, and give professional advice on clinical aspects, will become the key to whether pharmaceutical representatives can gain a foothold in the industry.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.